What is the mechanism of action of nitrates and why are they contraindicated in patients with patent ductus arteriosus (PDA) who have Eisenmenger syndrome?

Mechanism of Action of Nitrates and Contraindication in PDA with Eisenmenger Syndrome

Mechanism of Action

Nitrates work by undergoing enzymatic denitrification in the vessel wall via mitochondrial aldehyde dehydrogenase to produce nitric oxide (NO), which causes vasodilation 1. This mechanism is endothelium-independent, meaning nitrates can produce NO in both endothelial cells and vascular smooth muscle myocytes regardless of endothelial function 2.

Hemodynamic Effects by Dose:

• Low doses: Predominantly venodilation → reduces preload and venous return → decreases ventricular volume and myocardial wall tension → lowers myocardial oxygen demand 1

• Higher doses: Also dilate coronary arteries, prevent coronary spasm, improve subendocardial blood flow, decrease ventricular diastolic pressure, and lower blood pressure 1

The effects on preload and afterload trigger reflex sympathetic activation, causing increased heart rate and myocardial contractility that partially offset the reduction in myocardial oxygen consumption 2. This is why combining nitrates with beta-blockers produces synergistic anti-ischemic effects by blocking the reflex tachycardia 1.

Additional Mechanisms:

• Dilate normal and atherosclerotic coronary arteries
• Increase coronary collateral flow
• May inhibit platelet aggregation 2

Important caveat: Small arterioles are nitrate-resistant, explaining why nitrates have minimal action in the microcirculation 1.

---

Why Nitrates Are Contraindicated in PDA with Eisenmenger Syndrome

Nitrates are absolutely contraindicated in patients with PDA and Eisenmenger syndrome because systemic vasodilation will worsen the already reversed (right-to-left) shunt, dramatically increasing cyanosis and potentially causing cardiovascular collapse.

Pathophysiology of the Contraindication:

In Eisenmenger syndrome with PDA, there is suprasystemic pulmonary vascular resistance causing right-to-left shunting through the ductus arteriosus, sending deoxygenated blood from the pulmonary artery directly into the descending aorta 3, 4. This creates the characteristic differential cyanosis (lower body more cyanotic than upper body) 5.

Why Nitrates Are Dangerous:

1. Systemic vasodilation predominates: Nitrates primarily cause systemic arterial and venous dilation, which reduces systemic vascular resistance (SVR) 1, 2, 1

2. Worsens the pressure gradient: When SVR drops while pulmonary vascular resistance remains fixed and elevated, the pressure gradient favoring right-to-left shunting increases dramatically

3. Increased deoxygenated blood flow: More deoxygenated blood shunts from the pulmonary artery into the systemic circulation, severely worsening cyanosis and systemic oxygen delivery

4. Hypotension risk: The combination of systemic vasodilation and reduced cardiac output from worsened shunting can cause profound hypotension 2

5. No pulmonary benefit: Nitrates have minimal effect on small pulmonary arterioles (which are nitrate-resistant), so they cannot reduce the elevated pulmonary vascular resistance that is the fundamental problem 1

Clinical Context:

The 2014 AHA/ACC guidelines explicitly state that nitrates should not be administered to patients with hypotension 2, and patients with Eisenmenger syndrome are particularly vulnerable to hypotensive episodes. The guidelines also note that nitrates are administered with caution to patients with right ventricular infarction 2 due to preload dependence—a similar hemodynamic concern exists in Eisenmenger syndrome where the right ventricle is already under severe pressure overload 3.

Appropriate Management Instead:

For PDA with Eisenmenger syndrome, the evidence supports:

• Pulmonary arterial hypertension (PAH)-targeted medications (endothelin receptor antagonists like bosentan, PDE5 inhibitors) that specifically reduce pulmonary vascular resistance 3, 6, 7
• Avoiding all systemic vasodilators including nitrates, which worsen the shunt physiology
• Consideration for transcatheter closure only in highly selected patients after prolonged PAH-targeted therapy (≥12 months) demonstrates improved Qp/Qs ratio >1.5 with acute vasodilator testing 6, 7

The fundamental principle: Any medication that preferentially dilates the systemic circulation without adequately reducing pulmonary vascular resistance will worsen right-to-left shunting and cyanosis in Eisenmenger syndrome.